PL371368A1 - Doustna postać dawkowania do regulowanego uwalniania leku - Google Patents

Doustna postać dawkowania do regulowanego uwalniania leku

Info

Publication number: PL371368A1
Authority: PL; Poland
Prior art keywords: dosage form; oral dosage; drug release; controlled drug; controlled
Prior art date: 2002-02-12

Application number

PL03371368A

Other languages

English (en)

Other versions

PL206596B1 (pl

Inventor

Luigi Martini

Vincenzo Re

Chi Leung Li

Helen Anne Willy

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-12

Filing date

2003-02-12

Publication date

2005-06-13

2002-02-12 Priority claimed from GB0203298A external-priority patent/GB0203298D0/en

2002-02-12 Priority claimed from GB0203297A external-priority patent/GB0203297D0/en

2002-02-12 Priority claimed from GBGB0203296.9A external-priority patent/GB0203296D0/en

2003-02-12 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2005-06-13 Publication of PL371368A1 publication Critical patent/PL371368A1/pl

2010-08-31 Publication of PL206596B1 publication Critical patent/PL206596B1/pl

Links

238000013267 controlled drug release Methods 0.000 title 1
239000006186 oral dosage form Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL371368A 2002-02-12 2003-02-12 Doustna postać dawkowania 5-[4-2-(N-metylo-N-(2-pirydylo)amino)-etoksy]benzylo]tiazolidyno-2,4-dionu, lub jego farmaceutycznie dopuszczalnej soli albo solwatu, oraz sposób jej wytwarzania PL206596B1 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0203298A GB0203298D0 (en)	2002-02-12	2002-02-12	Novel composition
GB0203297A GB0203297D0 (en)	2002-02-12	2002-02-12	Novel composition
GBGB0203296.9A GB0203296D0 (en)	2002-02-12	2002-02-12	Novel composition

Publications (2)

Publication Number	Publication Date
PL371368A1 true PL371368A1 (pl)	2005-06-13
PL206596B1 PL206596B1 (pl)	2010-08-31

Family

ID=27738830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL371368A PL206596B1 (pl)	2002-02-12	2003-02-12	Doustna postać dawkowania 5-[4-2-(N-metylo-N-(2-pirydylo)amino)-etoksy]benzylo]tiazolidyno-2,4-dionu, lub jego farmaceutycznie dopuszczalnej soli albo solwatu, oraz sposób jej wytwarzania

Country Status (33)

Country	Link
EP (1)	EP1474114B1 (pl)
JP (2)	JP2005526031A (pl)
KR (2)	KR101048925B1 (pl)
CN (1)	CN100444833C (pl)
AP (1)	AP1736A (pl)
AR (1)	AR038417A1 (pl)
AT (1)	ATE455540T1 (pl)
AU (1)	AU2003245763B2 (pl)
BR (1)	BRPI0307319B8 (pl)
CA (1)	CA2475544A1 (pl)
CL (1)	CL2007003010A1 (pl)
CO (1)	CO5601025A2 (pl)
CY (1)	CY1109939T1 (pl)
DE (1)	DE60331041D1 (pl)
DK (1)	DK1474114T3 (pl)
EA (1)	EA008286B1 (pl)
EC (1)	ECSP045232A (pl)
ES (1)	ES2336319T3 (pl)
IL (1)	IL163098A (pl)
IS (1)	IS2747B (pl)
MA (1)	MA27689A1 (pl)
MX (1)	MXPA04007794A (pl)
MY (1)	MY139719A (pl)
NO (1)	NO334453B1 (pl)
NZ (1)	NZ534152A (pl)
OA (1)	OA12770A (pl)
PE (1)	PE20030800A1 (pl)
PL (1)	PL206596B1 (pl)
PT (1)	PT1474114E (pl)
SI (1)	SI1474114T1 (pl)
TW (1)	TWI286079B (pl)
UY (1)	UY27660A1 (pl)
WO (1)	WO2003068195A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0120835D0 (en)	2001-08-28	2001-10-17	Smithkline Beecham Plc	Process
GB0203296D0 (en)	2002-02-12	2002-03-27	Glaxo Group Ltd	Novel composition
US8637512B2 (en)	2002-07-29	2014-01-28	Glaxo Group Limited	Formulations and method of treatment
AR045330A1 (es) *	2003-08-07	2005-10-26	Sb Pharmco Inc	Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
US7879354B2 (en)	2004-01-13	2011-02-01	Mcneil-Ppc, Inc.	Rapidly disintegrating gelatinous coated tablets
JP5433236B2 (ja) *	2006-01-27	2014-03-05	アプタリスファーマテック，インコーポレイテッド	弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
US20070196491A1 (en) *	2006-01-27	2007-08-23	Eurand, Inc.	Drug delivery systems comprising weakly basic drugs and organic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2150830B (en) *	1983-12-05	1987-08-19	Alza Corp	Drug dispenser
GB8820353D0 (en) *	1988-08-26	1988-09-28	Staniforth J N	Controlled release tablet
US6099859A (en) *	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
DZ2937A1 (fr) *	1998-11-12	2004-03-15	Smithkline Beecham Plc	Compositions nouvelles de sensibilidants à l'insuline.
WO2000028989A1 (en) *	1998-11-12	2000-05-25	Smithkline Beecham P.L.C.	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB0027471D0 (en) *	2000-11-08	2000-12-27	Smithkline Beecham Plc	Processes

2003
- 2003-02-10 MY MYPI20030447A patent/MY139719A/en unknown
- 2003-02-10 PE PE2003000145A patent/PE20030800A1/es active IP Right Grant
- 2003-02-11 UY UY27660A patent/UY27660A1/es not_active IP Right Cessation
- 2003-02-11 AR ARP030100422A patent/AR038417A1/es not_active Application Discontinuation
- 2003-02-11 TW TW092102772A patent/TWI286079B/zh not_active IP Right Cessation
- 2003-02-12 EP EP03739557A patent/EP1474114B1/en not_active Expired - Lifetime
- 2003-02-12 CN CNB038037378A patent/CN100444833C/zh not_active Expired - Lifetime
- 2003-02-12 AP APAP/P/2004/003087A patent/AP1736A/en active
- 2003-02-12 ES ES03739557T patent/ES2336319T3/es not_active Expired - Lifetime
- 2003-02-12 WO PCT/GB2003/000594 patent/WO2003068195A1/en not_active Ceased
- 2003-02-12 NZ NZ534152A patent/NZ534152A/en not_active IP Right Cessation
- 2003-02-12 AT AT03739557T patent/ATE455540T1/de active
- 2003-02-12 CA CA002475544A patent/CA2475544A1/en not_active Abandoned
- 2003-02-12 BR BRPI0307319A patent/BRPI0307319B8/pt not_active IP Right Cessation
- 2003-02-12 PT PT03739557T patent/PT1474114E/pt unknown
- 2003-02-12 PL PL371368A patent/PL206596B1/pl unknown
- 2003-02-12 MX MXPA04007794A patent/MXPA04007794A/es active IP Right Grant
- 2003-02-12 OA OA1200400209A patent/OA12770A/en unknown
- 2003-02-12 KR KR1020047012361A patent/KR101048925B1/ko not_active Expired - Lifetime
- 2003-02-12 EA EA200401071A patent/EA008286B1/ru not_active IP Right Cessation
- 2003-02-12 KR KR1020107015064A patent/KR20100086084A/ko not_active Ceased
- 2003-02-12 AU AU2003245763A patent/AU2003245763B2/en not_active Expired
- 2003-02-12 SI SI200331764T patent/SI1474114T1/sl unknown
- 2003-02-12 JP JP2003567378A patent/JP2005526031A/ja not_active Withdrawn
- 2003-02-12 DE DE60331041T patent/DE60331041D1/de not_active Expired - Lifetime
- 2003-02-12 DK DK03739557.1T patent/DK1474114T3/da active
2004
- 2004-07-19 IL IL163098A patent/IL163098A/en active IP Right Grant
- 2004-08-05 IS IS7383A patent/IS2747B/is unknown
- 2004-08-09 CO CO04077244A patent/CO5601025A2/es not_active Application Discontinuation
- 2004-08-12 MA MA27822A patent/MA27689A1/fr unknown
- 2004-08-12 EC EC2004005232A patent/ECSP045232A/es unknown
- 2004-08-31 NO NO20043633A patent/NO334453B1/no not_active IP Right Cessation
2007
- 2007-10-19 CL CL2007003010A patent/CL2007003010A1/es unknown
2010
- 2010-03-31 CY CY20101100304T patent/CY1109939T1/el unknown
- 2010-04-22 JP JP2010098906A patent/JP5279757B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1474114B1 (en)	2010-01-20
OA12770A (en)	2006-07-04
CY1109939T1 (el)	2014-09-10
JP5279757B2 (ja)	2013-09-04
BRPI0307319B8 (pt)	2021-05-25
NZ534152A (en)	2006-11-30
DE60331041D1 (de)	2010-03-11
EA200401071A1 (ru)	2004-12-30
ES2336319T3 (es)	2010-04-12
PL206596B1 (pl)	2010-08-31
JP2010159301A (ja)	2010-07-22
AU2003245763B2 (en)	2008-12-11
KR20040084900A (ko)	2004-10-06
PE20030800A1 (es)	2003-10-31
SI1474114T1 (sl)	2010-04-30
NO20043633L (no)	2004-10-27
IS2747B (is)	2011-08-15
ECSP045232A (es)	2004-09-28
MY139719A (en)	2009-10-30
CL2007003010A1 (es)	2008-01-25
CA2475544A1 (en)	2003-08-21
AU2003245763A1 (en)	2003-09-04
UY27660A1 (es)	2003-09-30
CO5601025A2 (es)	2006-01-31
MXPA04007794A (es)	2004-10-15
NO334453B1 (no)	2014-03-03
TWI286079B (en)	2007-09-01
AP2004003087A0 (en)	2004-09-30
ATE455540T1 (de)	2010-02-15
DK1474114T3 (da)	2010-04-12
PT1474114E (pt)	2010-03-04
IS7383A (is)	2004-08-05
BR0307319A (pt)	2005-01-04
JP2005526031A (ja)	2005-09-02
BRPI0307319B1 (pt)	2018-05-02
MA27689A1 (fr)	2006-01-02
AR038417A1 (es)	2005-01-12
EA008286B1 (ru)	2007-04-27
CN100444833C (zh)	2008-12-24
CN1655768A (zh)	2005-08-17
WO2003068195A1 (en)	2003-08-21
EP1474114A1 (en)	2004-11-10
AP1736A (en)	2007-05-02
TW200307567A (en)	2003-12-16
HK1072194A1 (en)	2005-08-19
KR101048925B1 (ko)	2011-07-12
IL163098A (en)	2009-05-04
KR20100086084A (ko)	2010-07-29

Publication	Publication Date	Title
EP1553925A4 (en)	2012-09-05	ORAL DOSAGE FORM WITH MODIFIED RELEASE
PL373914A1 (pl)	2005-09-19	Postacie dawkowane o natychmiastowym uwalnianiu, zawierające stałe dyspersje leku
EP1648327A4 (en)	2013-11-13	ORAL DEVICES AND METHODS OF CONTROLLED MEDICAMENT DELIVERY
PL356358A1 (en)	2003-04-07	Solid dosage form of someticone for oral administration
IL166286A0 (en)	2006-01-15	Multicomponent pharmaceutical dosage form
GB0217225D0 (en)	2002-09-04	Medicinal compounds
GB0204719D0 (en)	2002-04-17	Medicinal compounds
GB0220730D0 (en)	2002-10-16	Medicinal compounds
AU2003221770A8 (en)	2003-11-17	Controlled release transdermal drug delivery
PL377495A1 (pl)	2006-02-06	Stały lek do stosowania doustnego
EG24479A (en)	2009-08-03	Modified release pharmaceutical formulation
ZA200501084B (en)	2006-03-29	Dispersible tablets for oral administration
EP1757273A4 (en)	2011-02-09	PREPARATION FOR ORAL ADMINISTRATION
EP1207852A4 (en)	2009-11-11	ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
PL376840A1 (pl)	2006-01-09	Kompozycja farmaceutyczna o przedłużonym uwalnianiu
FI20000780L (fi)	2001-10-04	Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
IL163887A0 (en)	2005-12-18	Controlled release dosage forms
AP2004003087A0 (en)	2004-09-30	Oral dosage form for controlled drug release
AU2003261067A8 (en)	2004-04-30	Modified release ketoprofen dosage form
HUP0401599A3 (en)	2007-03-28	Extended release oral dosage form
EP1357898A4 (en)	2005-07-13	ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
GB0322848D0 (en)	2003-10-29	Tetracycline controlled release pharmaceutical dosage form
EP1361866A4 (en)	2007-10-17	EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
AU2003254672A8 (en)	2004-02-25	Dual-spike release formulation for oral drug delivery
ZA200500409B (en)	2006-07-26	Multicomponent pharmaceutical dosage form